Clovis Oncology Inc. (NASDAQ:CLVS) saw a large growth in short interest during the month of September. As of September 30th, there was short interest totalling 12,649,940 shares, a growth of 15.8% from the September 15th total of 10,926,674 shares. Based on an average daily volume of 5,193,870 shares, the short-interest ratio is currently 2.4 days. Approximately 38.2% of the company’s stock are short sold.

Clovis Oncology (NASDAQ:CLVS) opened at 33.12 on Friday. The stock has a 50 day moving average of $30.85 and a 200 day moving average of $19.07. Clovis Oncology has a 52 week low of $11.57 and a 52 week high of $109.18. The company’s market cap is $1.28 billion.

Clovis Oncology (NASDAQ:CLVS) last posted its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($2.07) EPS for the quarter, beating the Zacks’ consensus estimate of ($2.13) by $0.06. During the same period last year, the company posted ($2.10) earnings per share. Equities research analysts predict that Clovis Oncology will post ($9.25) earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. CIBC World Markets Inc. increased its position in Clovis Oncology by 7.8% in the first quarter. CIBC World Markets Inc. now owns 11,680 shares of the biopharmaceutical company’s stock worth $224,000 after buying an additional 850 shares during the period. BlackRock Institutional Trust Company N.A. increased its position in shares of Clovis Oncology by 7.1% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 825,085 shares of the biopharmaceutical company’s stock valued at $15,842,000 after buying an additional 54,476 shares during the last quarter. Spark Investment Management LLC increased its position in shares of Clovis Oncology by 2.3% in the first quarter. Spark Investment Management LLC now owns 112,500 shares of the biopharmaceutical company’s stock valued at $2,160,000 after buying an additional 2,500 shares during the last quarter. State Street Corp increased its position in shares of Clovis Oncology by 21.2% in the first quarter. State Street Corp now owns 1,797,874 shares of the biopharmaceutical company’s stock valued at $34,525,000 after buying an additional 313,893 shares during the last quarter. Finally, Opus Point Partners Management LLC increased its position in shares of Clovis Oncology by 50.0% in the first quarter. Opus Point Partners Management LLC now owns 75,000 shares of the biopharmaceutical company’s stock valued at $1,440,000 after buying an additional 25,000 shares during the last quarter. 98.46% of the stock is owned by institutional investors and hedge funds.

CLVS has been the subject of a number of recent research reports. SunTrust Banks Inc. initiated coverage on shares of Clovis Oncology in a research report on Friday, August 5th. They set a “buy” rating and a $25.00 price objective for the company. Piper Jaffray Cos. reaffirmed a “hold” rating and set a $14.00 price objective on shares of Clovis Oncology in a research report on Wednesday, June 29th. Credit Suisse Group AG reaffirmed an “outperform” rating and set a $41.00 price objective on shares of Clovis Oncology in a research report on Monday. Zacks Investment Research downgraded shares of Clovis Oncology from a “buy” rating to a “hold” rating in a research report on Tuesday, October 4th. Finally, Stifel Nicolaus boosted their price objective on shares of Clovis Oncology from $30.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, September 21st. Seven analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $36.39.

Clovis Oncology Company Profile

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.

5 Day Chart for NASDAQ:CLVS

Receive News & Stock Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related stocks with our FREE daily email newsletter.